2013;369:999 1010. 305. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933 44. 306. AstraZeneca. Brilinta REMS document. NDA 22-433. 2011. 307. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010;31:35 49. 308. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coro- nary syndromes: the ACUITY Timing trial. JAMA. 2007;297:591 602. 309. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfrac- tionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45 54. 310. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203 16. 311. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary interven- tion: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907 19. 312. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syn- dromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50:1742 51. 313. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparininacutecoronarysyndromes.NEnglJMed.2006;354:1464 76. 314. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coro- nary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 315. 